echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Deep Guangpo cut another 30 kinds of drug prices! Shiguibao, Lilai, YANGSEN, etc

    Deep Guangpo cut another 30 kinds of drug prices! Shiguibao, Lilai, YANGSEN, etc

    • Last Update: 2018-06-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On June 5, quanyao.com released the notice on publicizing the price reduction of some traded varieties in the purchase catalogue of Shenzhen Public Hospital Pharmaceutical Group and the notice on publicizing the price reduction of online varieties in the cross regional joint centralized purchase of drugs of Dongguan public hospital In order to ensure the successful implementation of joint centralized drug purchase in public hospitals in Shenzhen and Dongguan, the group purchasing organization (GPO) was proposed in the notice According to the change of market price, the supply price of 30 transaction varieties in the group's procurement catalogue was lowered, and star varieties such as Squibb "boluting", Lilly "libitan", Janssen "spirino" and Sanofi "debarkin" were listed Under the GPO mode, Shenzhen centralized "package" the drug purchase demand of public hospitals and handed it to the third-party group purchasing organization (GPO) GPO negotiated with drug companies through "volume purchase" Before that, Shenzhen has formulated and released two batches of drug purchase catalogues, including the first batch of purchase catalogues (403 kinds) focusing on short drugs, low-cost drugs, first-aid and rescue drugs, and specialized drugs for women and children, and the second batch of purchase catalogues (643 kinds) focusing on chemical drugs, biological products, Chinese patent medicines and basic infusion Among the 30 varieties of price reduction released this time, Sanofi's children's epilepsy drug "sodium valproate oral solution (debaking)" and Haizheng Pfizer's gynecological cancer drug "bleomycin hydrochloride for injection" are the first batch of catalogue varieties, and the remaining 28 varieties are the second batch of catalogue varieties, The manufacturers include not only multinational pharmaceutical enterprises such as Shiguibao, Lilai, YANGSEN and the first three parties, but also domestic pharmaceutical enterprises such as Guangyao Baiyunshan, Jiangsu Haosen, yuekang pharmaceutical, Haizheng pharmaceutical and hisic In December last year, Shenzhen health and Family Planning Commission released a news report that 1159 kinds of drugs purchased according to the second batch of GPO (drug group purchasing organization) catalogues had an average decrease of 22.57%, among which the competitive varieties of more than two manufacturers had a decrease of 47.45% and the anti infective varieties had a decrease of 36.4% It is expected to save 1.537 billion yuan for Shenzhen public hospitals in the whole year Shenzhen GPO procurement in two batches data of price reduction of some varieties (data source: Official wechat of Shenzhen health and Family Planning Commission) In addition, the official data shows that the drug procurement catalogue also has a large degree of "slimming": in the GPO procurement catalogue in Shenzhen, 2451 product specifications and 40 dosage forms in the previous procurement channels were reduced to 1645 product specifications and 21 dosage forms, respectively "slimming" 32.9% and 47.5% The impact of the overall drop in drug prices varies Because of the large drop in chronic diseases, tumors and other drugs, such patients will feel the most profound, Taking chronic hepatitis B as an example, the annual drug burden of domestic entecavir has dropped from 5025.8 yuan to 1419.6 yuan Among the 30 price reduction varieties released this time, entecavir tablets (boluting) from Shanghai Squibb, China and the United States are among them, and the pressure of price reduction can be imagined After being investigated by the national development and Reform Commission, Shenzhen made timely amendments to the GPO centralized procurement policy, including three measures to ensure the autonomy of drug procurement in public hospitals, to ensure the autonomy of drug distribution enterprises, and to ensure the autonomy of drug manufacturers Dongguan, December 2017 The Municipal Leading Group for deepening medical reform held a mobilization meeting for the city's pharmaceutical cross regional joint procurement reform, which clearly connected with Shenzhen GPO to realize the procurement information networking; subsequently, the notice on registration and filing of pharmaceutical cross regional joint centralized procurement and distribution enterprises of public medical institutions in Dongguan required distribution enterprises willing to participate in the pharmaceutical cross regional joint centralized procurement for filing Up to now, in addition to Shanghai and Guangdong continuing to explore GPO in depth, GPO models across the country have also been implemented: in August 2017, Hubei issued the implementation opinions of the general office of the provincial people's Government on further reform and improvement of drug procurement and supply guarantee mechanism in public hospitals, and proposed the introduction of third-party group procurement organization (GPO) In December 2017, Gansu Province issued the 2017 implementation plan for centralized procurement of drugs for medical institutions in Gansu Province, encouraging and promoting the implementation of GPO procurement and online shopping mall procurement by medical institutions consortia in different regions and at different levels July 2017, Guangzhou The general office of the municipal government issued the notice on the implementation plan of the comprehensive reform of public hospitals in Guangzhou, defining 21 reform measures It proposed to establish a GPO (drug centralized procurement organization) platform based on the Guangzhou public resource trading center, promote the unified organization, bidding and procurement of drugs (medical consumables) in public hospitals in Guangzhou, and implement the unified distribution, Reduce the circulation link and control the cost of drugs (medical consumables) In April 2018, Guangdong pharmaceutical trading center and Foshan Municipal Bureau of human resources and social security held a strategic cooperation ceremony of "provincial and municipal co construction" Both parties decided to build "Foshan special area" with Foshan as the unit and relying on the third-party drug electronic trading platform of Guangdong Province, and Foshan Municipal Bureau of human resources and social security will organize public medical institutions to centrally purchase through the provincial platform.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.